Larimar Therapeutics (Larimar Therapeutics) Growth Rank : 0 (As of May. 26, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Larimar Therapeutics Growth Rank?

Larimar Therapeutics has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Larimar Therapeutics Growth Rank Related Terms

Thank you for viewing the detailed overview of Larimar Therapeutics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Larimar Therapeutics (Larimar Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Larimar Therapeutics Inc (NAS:LRMR) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

ZA71:Germany

Address

Three Bala Plaza East, Suite 506, Bala Cynwyd, PA, USA, 19004

Website

https://www.larimartx.com

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Executives

Gopi Shankar	officer: Chief Development Officer	C/O LARIMAR THERAPEUTICS, INC., THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD PA 19004
Jeffrey W Sherman	director	C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Russell Clayton	officer: Chief Medical Officer	2600 KELLY RD, WARRINGTON PA 18976
Carole Ben-maimon	director, officer: President and CEO	C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
Michael Celano	officer: Chief Financial Officer	220 EAST FIRST STREET, BETHLEHEM PA 18015
Joseph Truitt	director	C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Thomas Edward Hamilton	director	211 STUYVESANT AVE, RYE NY 10580
James E Flynn	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Jonathan S Leff	director	C/O DEERFIELD MANAGEMENT COMPANY, L.P, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Mgmt Hif, L.p.	director, 10 percent owner, other: Director by Deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Chondrial Therapeutics Holdings, Llc	10 percent owner	150 MONUMENT ROAD, SUITE 207, BALA CYNWYD PA 19004
Deerfield Mgmt Iv, L.p.	director, 10 percent owner, other: Director by Deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Private Design Fund Iv, L.p.	director, 10 percent owner, other: Director by Deputization	780 THIRD AVENUE 37TH FLOOR, NEW YORK NY 10017
Deerfield Healthcare Innovations Fund, L.p.	director, 10 percent owner, other: Director by Deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Mgmt Iii, L.p.	director, 10 percent owner, other: Director by Deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017